Back to results
US 2014/0275131 A1Published application
Organic compounds
AssigneeIntra-Cellular Therapies, Inc.
InventorsPeng LI, Hailin ZHENG, Jun ZHAO, Lawrence P. WENNOGLE
Life of this patent
Estimating the term…
Abstract
Provided are PDE1 inhibitors of Formula I, processes for their production, their use as pharmaceuticals, and pharmaceutical compositions comprising them.
Claims12
A compound of Formula I:
- wherein
- (i) R1 is H or C1-4 alkyl (e.g., methyl or ethyl);
- (ii) R2 and R3 are independently H or C1-6 alkyl (e.g., methyl or ethyl);
- (iii) R4 is H or C1-4 alkyl (e.g., methyl or ethyl);
- (iv) R5 is aryl (e.g., phenyl) optionally substituted with one or more groups independently selected from —C(═O)—C1-6 alkyl (e.g., —C(═O)—CH3) and C1-6-hydroxyalkyl (e.g., 1-hydroxyethyl);
- (v) R6 and R7 are independently H or aryl (e.g., phenyl) optionally substituted with one or more groups independently selected from C1-6 alkyl (e.g., methyl or ethyl) and halogen (e.g., F or Cl), for example unsubstituted phenyl or phenyl substituted with one or more halogen (e.g., F) or phenyl substituted with one or more C1-6 alkyl and one or more halogen or phenyl substituted with one C1-6 alkyl and one halogen, for example 4-fluorophenyl or 3,4-difluorophenyl or 4-fluoro-3-methylphenyl;
- and
- (vi) n is 1, 2, 3, or 4,
- in free or salt form.
6 more elements
7-21. (canceled)
26-30. (canceled)
Dependencies are inferred from the claim text.